Notably, immune checkpoint blockade (ICB) antibodies targeting the programmed cell death protein‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) axis, such as Nivolumab, Pembrolizumab, and Atezolizumab, have demonstrated initial high response rates in various malignancies.[4] However, a substantial portion of patients fail to derive long term benefits from this treatment, majority due to the rapid development of drug resistance.[5] Likewise, the efficacy of ICB therapy targeting the PD‐1/PD‐L1 axis in the treatment of advanced NSCLC remains unsatisfactory.[6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.